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Background
Since its discovery the chemokines receptor CCR5 that
acts as a required co-receptor for HIV-1 (R5) infection and
represents a key target for antivirals aiming at inhibiting
the HIV-1 entry process such as CCR5 specific antibodies
that have been shown to internalize the receptor and effi-
ciently block HIV entry. These antibodies been elicited in
mice upon specific antigen presentation of human CCR5
specific regions.
Methods
The aim of this study is to formal breaking tolerance and
to inducing infection-protecting anti-CCR5 auto-antibod-
ies in mice without signs of pathologic phenomenon. For
this purpose, we generated chimeric immunogens con-
taining the relevant autologous mouse CCR5 peptide in
the context of the capsid protein of Flock House Virus
(FHV), a molecular system particularly suitable for con-
taining looped peptide.
Results
Administered by intra-peritoneal or intra-nasal routes, the
immunogens elicited anti-CCR5 IgG and IgA (in serum
and vaginal fluids). In analogy with previous studies, mice
producing anti-CCR5 autoantibodies express significantly
reduced levels of CCR5 on the surface of CD4+ cells from
peripheral blood and vaginal washes. No signs of immu-
nopathology have been found in immunized mice. In
vitro studies have shown that murine IgG and IgA: i) spe-
cifically bind human and mouse CD4+ lymphocytes and
the CCR5-transfected U87 cell line; ii) down-modulate
CCR5 expression of cultured CD4+ cells from both
humans and untreated mice.
Conclusion
Results from these studies have been providing novel
direction for the development of durable HIV infection
prevention measures not restricted to specific HIV iso-
lates.
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